We have developed a novel colorimetric and ratiometric fluorescence probe for the selective and sensitive imaging of H2S in living cells and living zebrafish in vivo.
The global disruption caused by the 2020 coronavirus pandemic stressed the supply chain of many products, including pharmaceuticals. Multiple drug repurposing studies for COVID-19 are now underway. If a winning therapeutic emerges, it is unlikely that the existing inventory of the medicine, or even the chemical raw materials needed to synthesize it, will be available in the quantities required. Here, we utilize retrosynthetic software to arrive at alternate chemical supply chains for the antiviral drug umifenovir, as well as eleven other antiviral and anti-inflammatory drugs. We have experimentally validated four routes to umifenovir and one route to bromhexine. In one route to umifenovir the software invokes conversion of six C–H bonds into C–C bonds or functional groups. The strategy we apply of excluding known starting materials from search results can be used to identify distinct starting materials, for instance to relieve stress on existing supply chains.
Repurposing of amine and carboxylic acid building blocks provides an enormous opportunity to expand the accessible chemical space, because amine and acid feedstocks are typically low cost and available in high diversity. Herein, we report a copper-catalyzed deaminative esterification based on C–N activation of aryl amines via diazonium salt formation. The reaction was specifically designed to complement the popular amide coupling reaction. A chemoinformatic analysis of commercial building blocks demonstrates that by utilizing aryl amines, our method nearly doubles the available esterification chemical space compared to classic Fischer esterification with phenols. High-throughput experimentation in microliter reaction droplets was used to develop the reaction, along with classic scope studies, both of which demonstrated robust performance against hundreds of substrate pairs. Furthermore, we have demonstrated that this new esterification is suitable for late-stage diversification and for building-block repurposing to expand chemical space.
A series of 4-alkoxyquinazoline derivatives containing the 1,3,4-oxadiazole scaffold have been designed and synthesized, and their inhibitory activities were also tested against A549, MCF-7 and Hela. Of these compounds, 2-(3,4-dimethoxybenzyl)-5-((quinazolin-4-yloxy)methyl)-1,3,4-oxadiazole (compound 4j) showed the most potent inhibitory activity (IC50 = 0.23 μM for MCF-7, IC50 = 0.38 μM for A549 and IC50 = 0.32 μM for Hela) and the effect was better than the positive control drug Tivozanib (IC50 = 0.38 μM for MCF-7, IC50 = 0.62 μM for A549 and IC50 = 0.34 μM for Hela). A docking simulation was performed to position compound 4j into the VEGFR active site to determine the probable binding model. These results suggested that compound 4j with potent inhibitory activity in tumor growth inhibition may be a potential anticancer agent.